Evidence map›Paper›PMID 40142123›Full record

ArticleMolecules (Basel, Switzerland)2025

Tailoring the Composition of HA/PEG Mixed Nano-Assemblies for Anticancer Drug Delivery.

Beatrice Zurletti, Ilaria Andreana, Iris Chiara Salaroglio, Valeria Bincoletto, Maela Manzoli, Barbara Rolando, Paola Milla, Chiara Riganti, Barbara Stella, Silvia Arpicco

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Beatrice ZurlettiDepartment of Drug Science and Technology, University of Turin, Via Pietro Giuria 9, 10125 Turin, Italy.
Ilaria AndreanaDepartment of Drug Science and Technology, University of Turin, Via Pietro Giuria 9, 10125 Turin, Italy.ORCID 0000-0001-9457-3667
Iris Chiara SalaroglioDepartment of Oncology, Interdepartmental Center of Molecular Biotechnology "Guido Tarone", University of Turin, Via Nizza 44, 10126 Turin, Italy.ORCID 0000-0002-6043-3794
Valeria BincolettoDepartment of Drug Science and Technology, University of Turin, Via Pietro Giuria 9, 10125 Turin, Italy.ORCID 0000-0003-3862-4698
Maela ManzoliDepartment of Drug Science and Technology, University of Turin, Via Pietro Giuria 9, 10125 Turin, Italy.ORCID 0000-0002-4427-7939
Barbara RolandoDepartment of Drug Science and Technology, University of Turin, Via Pietro Giuria 9, 10125 Turin, Italy.ORCID 0000-0001-6138-1503
Paola MillaDepartment of Drug Science and Technology, University of Turin, Via Pietro Giuria 9, 10125 Turin, Italy.ORCID 0000-0002-4245-4161
Chiara RigantiDepartment of Oncology, Interdepartmental Center of Molecular Biotechnology "Guido Tarone", University of Turin, Via Nizza 44, 10126 Turin, Italy.ORCID 0000-0001-9787-4836
Barbara StellaDepartment of Drug Science and Technology, University of Turin, Via Pietro Giuria 9, 10125 Turin, Italy.ORCID 0000-0001-8266-6604
Silvia ArpiccoDepartment of Drug Science and Technology, University of Turin, Via Pietro Giuria 9, 10125 Turin, Italy.

Funding

Italian Ministry of Health PRIN 2022-2022ZBZFX3
6 · The paper itself

Abstract

Self-assembling amphiphilic polymers represent highly promising materials with emerging applications across various fields. In these polymers, the presence of hydrophilic and hydrophobic segments within their structure drives the self-assembly process in aqueous environments, leading to organized structures capable of incorporating lipophilic drugs. Their high chemical versatility enables the design of tailored structures to meet specific requirements, such as the active targeting ability, thereby broadening their potential applications. In this work, a polyethylene glycol-phospholipid conjugate was employed to form nanocarriers loaded with a lipophilic derivative of gemcitabine. To achieve nano-assemblies actively targeted towards cancer cells overexpressing the hyaluronic acid (HA) receptor CD44, a HA-phospholipid conjugate was co-formulated in various molar ratios (1%, 10%, and 20%). All formulations exhibited a mean diameter below 130 nm, a negative zeta potential (approximately -30 mV), and a high encapsulation efficiency (above 90%). These nano-assemblies demonstrated stability during storage and effectively released the encapsulated drug in a cell culture medium. Upon incubation with cancer cells, the nano-assemblies were internalized via a CD44 endocytosis-mediated mechanism, with the extent of internalization depending on the HA conjugate content. Consistently, cell viability studies revealed that the nanocarriers decorated with higher amounts of HA exerted a higher cytotoxicity, enabling a fine tuning of the nano-assembly properties.

Indexed as

Antineoplastic AgentsDrug CarriersDrug Delivery SystemsHyaluronic AcidNanoparticlesPolyethylene GlycolsCell Line, TumorCell SurvivalDeoxycytidineDrug LiberationGemcitabineHumansHyaluronan ReceptorsAntineoplastic AgentsDeoxycytidineDrug CarriersGemcitabineHyaluronan ReceptorsHyaluronic AcidPolyethylene GlycolsCD44 receptorhyaluronic acid conjugatenano-assembliestargeted drug delivery

Identifiers

PMID40142123
PMCPMC11945053

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.